DOCSLIB.ORG

Investor Information Information Investor Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Investor Information Information Investor Information Strategic report report Governance and and remuneration remuneration Financial statements statements Investor information information Investor information In this section Quarterly trend 244 Pharmaceuticals turnover 246 Vaccines turnover 248 Five year record 249 Product development pipeline 255 Products, competition and intellectual property 258 Principal risks and uncertainties 261 Share capital and control 276 Dividends 278 Financial calendar 2021 279 Annual General Meeting 2021 279 Tax information for shareholders 280 Shareholder services and contacts 282 US law and regulation 284 Group companies 287 Glossary of terms 299 GSK Annual Report 2020 243 Financial record Quarterly trend An unaudited analysis of the Group results is provided by quarter in Sterling for the financial year 2020. Income statement – Total 12 months 2020 Q4 2020 Q3 2020 Q2 2020 Q1 2020 Reported Pro-forma Reported Reported Reported Reported £m £% CER% CER% £m £% CER% £m £% CER% £m £% CER% £m £% CER% Turnover Pharmaceuticals 17,056 (3) (1) (1) 4,366 (4) (3) 4,192 (7) (3) 4,102 (5) (5) 4,396 6 6 Vaccines 6,982 (2) (1) (1) 2,012 15 16 2,032 (12) (9) 1,133 (29) (29) 1,805 19 19 Consumer Healthcare 10,033 12 14 (2) 2,360 (8) (7) 2,422 (4) 2 2,389 25 25 2,862 44 46 34,071 1 3 (2) 8,738 (1) – 8,646 (8) (3) 7,624 (2) (3) 9,063 18 19 Corporate and other unallocated turnover 28 1 – – 27 Total turnover 34,099 1 3 (2) 8,739 (2) (1) 8,646 (8) (3) 7,624 (2) (3) 9,090 19 19 Cost of sales (11,704) (1) – (3,171) (2) (2) (2,885) (11) (8) (2,449) (7) (7) (3,199) 17 18 Selling, general and administration (11,456) – 2 (3,162) (8) (6) (2,669) (8) (4) (2,709) 5 5 (2,916) 18 19 Research and development (5,098) 12 12 (1,470) 18 19 (1,140) (5) (2) (1,301) 17 15 (1,187) 18 18 Royalty income 318 (9) (9) 91 11 12 85 (28) (26) 75 (4) (10) 67 (8) (5) Other operating income/(expense) 1,624 34 (179) 1,610 159 Operating profit 7,78 3 12 15 1,061 (44) (44) 1,858 (13) (2) 2,850 92 90 2,014 41 42 Net finance costs (848) (234) (198) (228) (188) Share of after-tax profits/(losses) of associates and joint ventures 33 (6) 11 19 9 Profit before taxation 6,968 12 16 821 (52) (52) 1,671 (14) (2) 2,641 >100 >100 1,835 42 42 Taxation (580) 18 (241) (201) (156) Tax rate % 8.3% (2.2)% 14.4% 7.6% 8.5% Profit after taxation for the period 6,388 21 25 839 (45) (45) 1,430 (17) (5) 2,440 >100 >100 1,679 70 71 Profit attributable to non-controlling interests 639 162 186 177 114 Profit attributable to shareholders 5,749 677 1,244 2,263 1,565 Basic earnings per share (pence) 115.5p 23 26 13.6p (48) (48) 25.0p (20) (9) 45.5p >100 >100 31.5p 87 89 Diluted earnings per share (pence) 114.1p 13.4p 24.7p 45.0p 31.2p Income statement – Adjusted Total turnover 34,099 1 3 (2) 8,739 (2) (1) 8,646 (8) (3) 7,624 (2) (3) 9,090 19 19 Cost of sales (10,191) 1 2 (3) (2,792) (2) (2) (2,540) (9) (6) (2,249) – – (2,610) 18 20 Selling, general and administration (10,717) – 2 (3) (2,924) (6) (4) (2,477) (11) (7) (2,530) 4 4 (2,786) 16 18 Research and development (4,603) 6 7 6 (1,297) 11 12 (1,049) (10) (6) (1,171) 13 11 (1,086) 12 11 Royalty income 318 (9) (9) (9) 91 11 12 85 (28) (26) 75 (4) (10) 67 (8) (5) Operating profit 8,906 (1) 2 (3) 1,817 (2) (1) 2,665 (4) 4 1,749 (19) (21) 2,675 24 24 Net finance costs (844) (233) (197) (227) (187) Share of after-tax profits/(losses) of associates and joint ventures 33 (6) 11 19 9 Profit before taxation 8,095 (2) 1 1,578 (5) (5) 2,479 (5) 4 1,541 (21) (22) 2,497 23 23 Taxation (1,295) (220) (417) (316) (342) Tax rate % 16.0% 13.9% 16.8% 20.5% 13.7% Profit after taxation for the period 6,800 (2) 1 1,358 (6) (6) 2,062 (6) 3 1,225 (26) (27) 2,155 32 32 Profit attributable to non-controlling interests 1,031 195 287 267 282 Profit attributable to shareholders 5,769 1,163 1,775 958 1,873 Adjusted earnings per share (pence) 115.9p (6) (4) 23.3p (6) (5) 35.6p (8) 1 19.2p (37) (38) 37.7 p 25 26 The calculation of Adjusted results is described on page 51. 244 GSK Annual Report 2020 Strategic report Governance and remuneration Financial statements Investor information Financial record continued Quarterly trend Quarterly trend continued An unaudited analysis of the Group results is provided by quarter in Sterling for the financial year 2020. Income statement – Total 12 months 2020 Q4 2020 Q3 2020 Q2 2020 Q1 2020 Reported Pro-forma Reported Reported Reported Reported £m £% CER% CER% £m £% CER% £m £% CER% £m £% CER% £m £% CER% Turnover Pharmaceuticals 17,056 (3) (1) (1) 4,366 (4) (3) 4,192 (7) (3) 4,102 (5) (5) 4,396 6 6 Vaccines 6,982 (2) (1) (1) 2,012 15 16 2,032 (12) (9) 1,133 (29) (29) 1,805 19 19 Consumer Healthcare 10,033 12 14 (2) 2,360 (8) (7) 2,422 (4) 2 2,389 25 25 2,862 44 46 34,071 1 3 (2) 8,738 (1) – 8,646 (8) (3) 7,624 (2) (3) 9,063 18 19 Corporate and other unallocated turnover 28 1 – – 27 Total turnover 34,099 1 3 (2) 8,739 (2) (1) 8,646 (8) (3) 7,624 (2) (3) 9,090 19 19 Cost of sales (11,704) (1) – (3,171) (2) (2) (2,885) (11) (8) (2,449) (7) (7) (3,199) 17 18 Selling, general and administration (11,456) – 2 (3,162) (8) (6) (2,669) (8) (4) (2,709) 5 5 (2,916) 18 19 Research and development (5,098) 12 12 (1,470) 18 19 (1,140) (5) (2) (1,301) 17 15 (1,187) 18 18 Royalty income 318 (9) (9) 91 11 12 85 (28) (26) 75 (4) (10) 67 (8) (5) Other operating income/(expense) 1,624 34 (179) 1,610 159 Operating profit 7,78 3 12 15 1,061 (44) (44) 1,858 (13) (2) 2,850 92 90 2,014 41 42 Net finance costs (848) (234) (198) (228) (188) Share of after-tax profits/(losses) of associates and joint ventures 33 (6) 11 19 9 Profit before taxation 6,968 12 16 821 (52) (52) 1,671 (14) (2) 2,641 >100 >100 1,835 42 42 Taxation (580) 18 (241) (201) (156) Tax rate % 8.3% (2.2)% 14.4% 7.6% 8.5% Profit after taxation for the period 6,388 21 25 839 (45) (45) 1,430 (17) (5) 2,440 >100 >100 1,679 70 71 Profit attributable to non-controlling interests 639 162 186 177 114 Profit attributable to shareholders 5,749 677 1,244 2,263 1,565 Basic earnings per share (pence) 115.5p 23 26 13.6p (48) (48) 25.0p (20) (9) 45.5p >100 >100 31.5p 87 89 Diluted earnings per share (pence) 114.1p 13.4p 24.7p 45.0p 31.2p Income statement – Adjusted Total turnover 34,099 1 3 (2) 8,739 (2) (1) 8,646 (8) (3) 7,624 (2) (3) 9,090 19 19 Cost of sales (10,191) 1 2 (3) (2,792) (2) (2) (2,540) (9) (6) (2,249) – – (2,610) 18 20 Selling, general and administration (10,717) – 2 (3) (2,924) (6) (4) (2,477) (11) (7) (2,530) 4 4 (2,786) 16 18 Research and development (4,603) 6 7 6 (1,297) 11 12 (1,049) (10) (6) (1,171) 13 11 (1,086) 12 11 Royalty income 318 (9) (9) (9) 91 11 12 85 (28) (26) 75 (4) (10) 67 (8) (5) Operating profit 8,906 (1) 2 (3) 1,817 (2) (1) 2,665 (4) 4 1,749 (19) (21) 2,675 24 24 Net finance costs (844) (233) (197) (227) (187) Share of after-tax profits/(losses) of associates and joint ventures 33 (6) 11 19 9 Profit before taxation 8,095 (2) 1 1,578 (5) (5) 2,479 (5) 4 1,541 (21) (22) 2,497 23 23 Taxation (1,295) (220) (417) (316) (342) Tax rate % 16.0% 13.9% 16.8% 20.5% 13.7% Profit after taxation for the period 6,800 (2) 1 1,358 (6) (6) 2,062 (6) 3 1,225 (26) (27) 2,155 32 32 Profit attributable to non-controlling interests 1,031 195 287 267 282 Profit attributable to shareholders 5,769 1,163 1,775 958 1,873 Adjusted earnings per share (pence) 115.9p (6) (4) 23.3p (6) (5) 35.6p (8) 1 19.2p (37) (38) 37.7 p 25 26 The calculation of Adjusted results is described on page 51. GSK Annual Report 2020 245 Financial record continued Pharmaceutical turnover by therapeutic area 2020 Total US Europe International 2020 2019 Growth 2020 Growth 2020 Growth 2020 Growth Therapeutic area/major products £m £m £% CER% £m £% CER% £m £% CER% £m £% CER% Respiratory 3,749 3,081 22 23 2,114 21 23 944 21 20 691 24 27 Ellipta products 2,755 2,313 19 20 1,516 18 19 706 22 22 533 19 22 Anoro Ellipta 547 514 6 8 327 1 2 142 18 17 78 11 17 Arnuity Ellipta 45 48 (6) (6) 37 (10) (7) – – – 8 14 – Incruse Ellipta 220 262 (16) (15) 117 (27) (27) 74 1 1 29 4 7 Relvar/Breo Ellipta 1,124 971 16 17 474 24 25 322 14 13 328 6 9 Trelegy Ellipta 819 518 58 59 561 47 48 168 65 65 90 >100 >100 Nucala 994 768 29 30 598 32 33 238 16 15 158 45 46 HIV 4,876 4,854 – 1 3,005 – 1 1,213 5 4 658 (5) (1) Dolutegravir products 4,702 4,633 1 2 2,941 – 1 1,163 7 6 598 (2) 3 Tivicay 1,527 1,662 (8) (7) 871 (11) (10) 368 (7) (8) 288 (1) 5 Triumeq 2,306 2,549 (10) (9) 1,454 (10) (9) 568 (9) (10) 284 (9) (6) Juluca 495 366 35 36 387 28 29 97 73 71 11 57 71 Dovato 374 56 >100 >100 229 >100 >100 130 >100 >100 15 >100 >100 Epzicom/Kivexa 31 75 (59) (59) 1 (67) (67) 9 (61) (61) 21 (57) (57) Selzentry 91 97 (6) (5) 47 (11) (11) 27 (7) (7) 17 13 20 Rukobia 11 – – – 11 – – – – – – – – Other 41 49 (16) (12) 5 (50) (40) 14 (22) (17) 22 5 5 Immuno-inflammation 727 613 19 20 612 14 16 56 22 20 59 84 91 Benlysta 719 613 17 19 612 14 16 56 22 20 51 59 66 Oncology 372 230 62 62 231 72 74 136 42 40 5 – – Zejula 339 229 48 48 206 54 55 128 35 33 5 – – Blenrep 33 – – – 25 – – 8 – – – – – Pharmaceuticals excluding established products 9,724 8,778 11 12 5,962 10 11 2,349 13 12 1,413 10 14 Established pharmaceuticals 7,332 8,776 (16) (15) 1,489 (25) (24) 1,755 (14) (15) 4,088 (14) (11) Established Respiratory 3,251 3,900 (17) (15) 1,048 (26) (25) 738 (9) (9) 1,465 (13) (10) Seretide/Advair 1,535 1,730 (11) (10) 434 (14) (13) 449 (11) (11) 652 (10) (7) Flixotide/Flovent 419 629 (33) (32) 183 (50) (50) 80 (9) (10) 156 (10) (5) Ventolin 785 938 (16) (14) 430 (21) (20) 116 (3) (4) 239 (12) (7) Avamys/Veramyst 297 324 (8) (6) – – – 66 (4) (4) 231 (10) (7) Other Respiratory 215 279 (23) (23) 1 >100 >100 27 (4)
Load more

Recommended publications
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* GENOCEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 372427 10 4 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 30, 2015 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    [Show full text]
  • Corporate Governance
    Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 78 The Board 80 Corporate Executive Team 83 Board architecture 85 Board roles and responsibilities 86 Board activity and principal decisions 87 Our purpose, values and culture 90 The Board’s approach to engagement 91 Board performance 94 Board Committee information 96 Our Board Committee reports 97 Section 172 statement 108 Directors’ report 109 GSK Annual Report 2020 77 Chairman’s Governance statement In last year’s Governance statement, I explained that our primary Education and focus on Science objective for 2020 was to ensure there was clarity between the Given the critical importance of strengthening the pipeline, Board and management on GSK’s execution of strategy and its the Board has benefitted from devoting a higher proportion of operational priorities. We have aligned our long-term priorities its time in understanding the science behind our strategy and of Innovation, Performance and Trust powered by culture testing its application. It is important that the Board has a and agreed on the metrics to measure delivery against them. working understanding of the key strategic themes upon The Board’s annual cycle of meetings ensures that all major which our R&D strategy is based. These themes have been components of our strategy are reviewed over the course complemented by Board R&D science thematic deep dives. of the year. Our focus was on the fundamentals of our strategy: human The COVID-19 pandemic impacted and dominated all our genetics, the immune system and AI and ML, as well as to lives for the majority of 2020.
    [Show full text]
  • Governance and Remuneration 2014
    Governance & remuneration reportStrategic In this section Our Board 72 Our Corporate Executive Team 76 Chairman’s letter 78 Corporate governance framework 79 Board report to shareholders Oversight and stewardship in 2014 and future actions 80 remuneration & Governance Leadership and effectiveness 82 Committee reports Audit & Risk 86 Nominations 92 Corporate Responsibility 94 Remuneration report Chairman’s annual statement 96 Annual report on remuneration 97 2014 Remuneration policy report 119 Financial statements Financial Investor information Investor GSK Annual Report 2014 71 Our Board Strategic reportStrategic Diversity Experience International experience Composition Tenure (Non-Executives) % % % % Scientific 19 Global 75 Executive 19 Up to 3 years 39 % % % % Finance 31 USA 100 Non-Executive 81 3-6 years 15 % % % % Industry 50 Europe 94 Male 69 7-9 years 23 % % % EMAP 63 Female 31 Over 9 years 23 Sir Christopher Gent 66 Skills and experience Chairman Sir Christopher has many years of experience of leading global businesses and a track record of delivering outstanding performance Governance & remuneration & Governance Nationality in highly competitive industries. He was appointed Managing Director British of Vodafone plc in 1985 and then became its Chief Executive Officer Appointment date in 1997 until his retirement in 2003. Sir Christopher was also a 1 June 2004 and as Chairman Non-Executive Director of Ferrari SpA and a member of the British on 1 January 2005 Airways International Business Advisory Board. Committee membership External appointments Corporate Responsibility Sir Christopher is a Senior Adviser at Bain & Co. Committee Chairman, Nominations, Remuneration and Finance Sir Philip Hampton 61 Skills and experience Chairman Designate Prior to joining GSK, Sir Philip chaired major FTSE 100 companies including J Sainsbury plc.
    [Show full text]
  • PEDIARIX Is a Vaccine
    HIGHLIGHTS OF PRESCRIBING INFORMATION • If Guillain-Barré syndrome occurs within 6 weeks of receipt of a prior These highlights do not include all the information needed to use vaccine containing tetanus toxoid, the decision to give PEDIARIX should PEDIARIX safely and effectively. See full prescribing information for be based on potential benefits and risks. (5.2) PEDIARIX. • The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions. (5.3) PEDIARIX [Diphtheria and Tetanus Toxoids and Acellular Pertussis • Syncope (fainting) can occur in association with administration of Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus injectable vaccines, including PEDIARIX. Procedures should be in place Vaccine], Suspension for Intramuscular Injection to avoid falling injury and to restore cerebral perfusion following Initial U.S. Approval: 2002 syncope. (5.4) • If temperature ≥105°F, collapse or shock-like state, or persistent, ----------------------------- INDICATIONS AND USAGE ---------------------------- PEDIARIX is a vaccine indicated for active immunization against diphtheria, inconsolable crying lasting ≥3 hours have occurred within 48 hours after tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, receipt of a pertussis-containing vaccine, or if seizures have occurred and poliomyelitis. PEDIARIX is approved for use as a 3-dose series in infants within 3 days after receipt of a pertussis-containing vaccine, the decision born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX to give PEDIARIX should be based on potential benefits and risks. (5.5) may be given as early as 6 weeks of age through 6 years of age (prior to the • For children at higher risk for seizures, an antipyretic may be 7th birthday).
    [Show full text]
  • Final Attendee List
    Jennifer Abnet GlaxoSmithKline I GlaxoSmithKline I Jane Arboleda APRN Guardant I Molly Benson Sanjiv Agarwala MD Puma Biotechnology I Cancer Expert Now I Joe Arminger AbbVie I Seth Berkowitz LCSW, Manmeet Ahluwalia MD, CCLS MBA Patricia Armstrong The Leukemia & Lymphoma Miami Cancer Institute I Novartis I Society V Steve Albers Kim Arnold APRN CPNP Barry Berman MD, MS Alexion V CPHON Florida Cancer Specialists I Servier Pharmaceuticals I Maritza Alencar DNP, Tizano Bernard MBA, APRN, BMTCN Sheila Arrington MSN, Cancer Care Centers of Miami Cancer Institute V APRN, NP-C, AOCN Brevard I Puma Biotechnology I Carmen Allen MSIT Ana Mari Bernardini Pharmavoxx V Shannon Ashmon Novartis Oncology I Eisai, Inc I Luly Almeida Bernard Berry MBA Incyte Corporation I Sarah Ashton MS AstraZeneca Pharmaceuticals Guardant Health I I Talat Almukhtar MD Orlando Health Cancer Melissa Austin Jason Bever Institute I Cancer Care Centers of Oncopeptides I Brevard I Beatrice Alvarado Roberts Amy Bignon MD Garland Avera Doyle Caris Life Sciences I University of Florida I Jazz Pharmaceuticals I Nadeem Bilani MD Tadeu Ambros MD Francie Babcock Cleveland Clinic I FCS I AMAG Pharmaceuticals/Covis I Angela Bilik RN BSN Douglas Anderson AstraZeneca I Incyte Corporation I Craig Bailey Astra Zeneca I Jamie Bilsky BS Blesson Andrews Genentech V Genentech I Kevin Barr Daiichi Sankyo I Rohit Bishnoi MD Ollie Annum PharmD University of Florida I BHMCR I Leonard Bennett PharmD EMD Serono I Brady Blackman Susmitha Apuri MD MorphoSys I Florida Cancer Specialists I Michael Bennett As of 4-22-21 Kimberly Blandon RN MSN Rick Breitenstein Memorial Cancer Institute I Apellis Pharmaceuticals I Denise Capo Karyopharm Therapeutics I Taryn Boiteau GlaxoSmithKline I Amanda Bridges Florida Society of Clinical Heidi Caravetta Tracy Bonds RN, BSN, Oncology I Exelixis, Inc.
    [Show full text]
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
    [Show full text]
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • Annual Review 2005
    GS2184_Review_A\W2.qxd 7/3/06 4:58 pm Page fc1 Annual Review 2005 human being Do more, feel better, live longer GS2184_Review_A\W2.qxd 9/3/06 1:28 pm Page ifc2 01 An interview with Sir Christopher Gent, Chairman, and JP Garnier, Chief Executive Officer 05 Tachi Yamada, Chairman, Research & Development, Pharmaceuticals 06 Jean Stéphenne, President and General Manager, GSK Biologicals 08 John Clarke, President, Consumer Healthcare 11 David Stout, President, Pharmaceutical Operations 14 Performance highlights 15 Business operating review 18 The Board 19 The Corporate Executive Team 20 Summary remuneration report 23 Corporate governance 24 Responsibility statements 25 Summary financial statements 26 Summary information under US GAAP 27 Shareholder information 29 Chairman and CEO’s closing letter JP Garnier (left) and Sir Christopher Gent (right) GS2184_Review_A\W2.qxd 7/3/06 5:01 pm Page 01 “Discovering important medicines, eradicating diseases, improving the quality of people’s lives and making medicines available to a greater number of people. This is what we do – and what we do matters to people.” JP Garnier, Chief Executive Officer An interview with Sir Christopher Gent, Chairman and JP Garnier, Chief Executive Officer 2005: a year of success and progress “Thanks to the efforts of our employees around the company’s pipeline is one of the largest and most world, 2005 was a very successful year for GSK,” says promising in the industry, with 149 projects in clinical JP Garnier, Chief Executive Officer. “Not only was it development (as at the end of February 2006), our best year ever from a financial standpoint, we also including 95 new chemical entities (NCEs), 29 product made substantial progress with our pipeline of line extensions (PLEs) and 25 vaccines.
    [Show full text]
  • Other Statutory Disclosures Continued
    Other statutory disclosures continued Strategic reportGroup companies Governance & remuneration Financial statements In accordance with Section 409 of the Companies Act 2006 a full list of subsidiaries, associates, joint ventures and joint arrangements, the country of incorporation and effective percentage of equity owned, as at 31 December 2015 are disclosed below. Unless otherwise stated the share capital disclosed comprises ordinary shares which are indirectly held by GlaxoSmithKline plc. All subsidiary companies are resident for tax purposes in their country of incorporation unless otherwise stated. Country of Effective % % Held by Name incorporation Ownership Security Class of Share Wholly owned subsidiaries 1506369 Alberta ULC Canada 100 Common 100 Action Potential Venture Capital Limited England & Wales 100 Ordinary 100 Adechsa GmbH Switzerland 100 Ordinary 100 Affymax Research Institute United States 100 Common 100 Alenfarma – Especialidades Farmaceuticas, Limitada (iv) Portugal 100 Ordinary Quota 100 Allen & Hanburys Limited (iv) England & Wales 100 Ordinary 100 Allen & Hanburys Pharmaceutical Nigeria Limited Nigeria 100 Ordinary 100 Allen Farmaceutica, S.A. Spain 100 Ordinary 100 Allen Pharmazeutika Gesellschaft m.b.H. Austria 100 Ordinary 100 Aners S.A (iv) Argentina 100 Non-endorsable Nominative Ordinary 100 Barrier Therapeutics, Inc. United States 100 Common 100 Beecham Group p l c England & Wales 100 20p Shares 'A'; 5p Shares B 100 Beecham Pharmaceuticals (Pte) Limited Singapore 100 Ordinary 100 Beecham Pharmaceuticals S.A (iv) (vi) Ecuador 100 Nominative 100 Beecham Portuguesa-Produtos Farmaceuticos e Quimicos, Lda Portugal 100 Ordinary Quota 100 Beecham S.A. (iv) Belgium 100 Ordinary 100 Biddle Sawyer Limited India 100 Equity 100 Biovesta Ilaçlari Ltd. Sti. Turkey 100 Nominative 100 Burroughs Wellcome & Co (Australia) Pty Limited (iv) (vi) Australia 100 Ordinary 100 Burroughs Wellcome & Co (Bangladesh) Limited Bangladesh 100 Ordinary 100 Burroughs Wellcome International Limited England & Wales 100 Ordinary 100 Caribbean Chemical Company, Ltd.
    [Show full text]
  • Cross Reaction Guide
    Individual Reaction Key Methadone(MTD) Phencyclidine(PCP) Amphetamines(AMP) Tricyclic Antidepressants(TCA) Oxycodone(OXY) Barbiturates(BAR) Methamphetamines(MET) Benzodiazepines(BZO) Tramadol(TML) Opiates(OPI, MOP, MOR) Marijuana(THC) Ecstasy(MDMA) Cotinine(COT) Cocaine(COC) Buprenorphine(BUP) Propoxyphene(PPX) Non-reactive Multiple Reaction Key MET and AMP OPI and OXY MDMA and MET MDMA and AMP MET and TCA Generic Name of Compound Trade Name of Compound Results 6-Acetylmorphine N/A Positive: Opiates(OPI, MOP, MOR) Aceta, Acephen, Apacet, Dapacen, Feverall, Acetaminophen (aka Paracetamol) Tylenol, Excedrin (combination), Panadol, Non-reactive Tempra Acetaminophen with Codeine (aka Positive: Opiates(OPI, MOP, MOR) Tylenol 3, Tylenol with Codeine Paracetamol with Codeine) Potential reactants: Dihydrocodeine Acetophenetidin Phenacetin Non-reactive Aspirin, Anadin, Anasin, Bufferin, Caprin, Acetylsalicyclic Acid Disprin, Ecotrin, Empirin, Excedrin Non-reactive (combination) Allobarbital N/A Positive: Barbiturates(BAR) Alphenol N/A Positive: Barbiturates(BAR) Positive: Benzodiazepines(BZO) Potential Alprazolam Xanax reactants: Oxaprozin (Daypro), Sertraline Aluminum Chloride Hexahydrate Drichlor, Anhydrol Forte Non-reactive Alu-Cap, Alisone, Gastrocote, Kolanticon, Aluminum Hydroxide Non-reactive Maalox TC, Mucogel, Pyrogastrone, Topal Alverine Citrate Spasmonal, Spasmonal Fibre Non-reactive Amantadine Symmetrel Positive: Amphetamines(AMP) SpearesMedical.comAminopyrine N/A Non-reactive Elavil, Lentizol, Tryptizol, Triptafen, Triptafen- Amitriptyline
    [Show full text]
  • GSK Q1 Report 2021
    Calibrating Precision GSK Pakistan Limited FirstAnnual Quarter Report Report 20212020 CORPORATE INFORMATION As at March 31, 2021 Board of Directors Management Committee Disclosure Committee Mr. Dmytro Oliinyk Ms. Erum Shakir Rahim Ms. Erum Shakir Rahim Chairman Chief Executive Officer Chairperson Ms. Erum Shakir Rahim Mr. Abdul Samad* Mr. Abdul Samad* Chief Executive Officer Chief Financial Officer Member Mr. Abdul Samad* Mehar-e-daraksha Ameer Mr. Dmytro Oliinyk Chief Financial Officer Legal Director Member Ms. Maheen Rahman Dr. Tariq Farooq Mehar-e-daraksha Ameer Independent Director Business Unit Director BU 1 Member Mr. Muneer Kamal Syed Nasir Farid** Company Secretary Independent Director Business Unit Director BU 2 Ms. Mehar-e-daraksha Ameer Mr. Mehmood Mandviwalla Dr. Naved Masoom Ali Non-Executive Director Business Unit Director BU 3 Chief Financial Officer Mr. Mark Dawson Khurram Amjad Mr. Abdul Samad* Non-Executive Director Director Commercial Chief Internal Auditor Excellence & CTC Audit Committee Syed Ahsan Ejaz Dr. Gohar Nayab Khan Mr. Muneer Kamal Regulatory Affairs Cluster Bankers Chairman Head - Pakistan & Iran Citibank NA Mr. Dmytro Oliinyk Mr. Abdul Haseeb Pirzada Deutsche Bank A.G. Member Director Corporate Affairs and Habib Bank Limited Administration Meezan Bank Limited Mr. Mark Dawson Standard Chartered Bank (Pakistan) Ltd Member Mr. Zain Anjum Country Compliance Officer Auditors Mr. Mehmood Mandviwalla Member Dr. Yousuf Hasan Khan Yousuf Adil & Co. Chartered Director Medical Accountants Ms. Maheen Rahman Member Syed Nabigh Raza Alam Legal Advisors Tech Head Hashmi & Hashmi Human Resource Mr. Obaid Siddiqui Faisal, Mahmood Ghani and Co & Remuneration Head of Procurement Legal Consultancy Inc. Committee Mr. Farqaleet Iqbal Registered Office Mr.
    [Show full text]
  • GSK Annual Report 2016
    Annual Report Transcending boundaries is in our DNA. This is evident in how we continue to discover, develop and bring to market, new medicines and vaccines to address the unmet needs of healthcare providers and their patients. As a responsible healthcare company, we drive change by adopting new and innovative methodologies, aligned with our values, so that we can better serve the evolving needs of our society and enable more patients to benefit from our medicines. We firmly believe that keeping the patient at the heart of everything we do is integral to our success; inspiring us to continue on this journey and transcend boundaries. GSK Contents 002 026 062 Our Vision, Mission and Core Vaccines Key Operating and Financial Data Values 028 065 004 Primary Care Direct Cash Flow Statement Corporate Information 030 066 006 Specialty Business Unit Horizontal Analysis Financial Highlights 031 067 007 Medical Affairs Vertical Analysis DUPONT Analysis 032 070 008 Awards 2016 Statement of Compliance with the The GSK Story 034 Code of Corporate Governance 010 Global Manufacturing & Supply 072 GSK Expectations (GMS) Review Report to the Members 011 035 073 Strategic Priorities Warehousing and Auditors Report to the Members 012 Distribution (W&D) 074 Company Profile & 036 Balance Sheet Group Structure Environment Health & Safety (EHS) 075 014 Profit and Loss Account Our Behaviour 038 Quality Management System (QMS) 076 015 Cash Flow Statement Organogram 040 Corporate Social Responsibility 077 016 (CSR) Statement of Changes in Equity Geographical Presence
    [Show full text]